0      0


5949 - Jardiance® (empagliflozin) tablets: A Review of Multiple Clinical Trials and Approved Indications—Presented by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA


‐ Jun 24, 2023 1:30pm


Speaker(s):

You must be logged in and own this session in order to post comments.